CABOZANTINIB LAURYLSULFATE
| Brand name | OMCAZIO |
|---|---|
| Active ingredient | CABOZANTINIB LAURYLSULFATE |
| Strength | EQ 23MG BASE |
| Dosage form | CAPSULE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | September 2026 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 12552749 | January 2044 | use U-1480 |
| 12552567 | January 2044 | use U-4131 |
| 12516025 | January 2044 | use U-4131 |
| 12741938 | January 2044 | product |
| 12415784 | January 2044 | — |
| 12064430 | June 2039 | use U-2488 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.